Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 75 of 110 Updated Nov 17, 2026

Decapeptide-12

Lumixyl

COSMETIC CLINICAL STUDIES · COSMETIC PEPTIDE; TYROSINASE INHIBITOR

▓ 9 indexed citations across PubMed (7), EuropePMC (2).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

9 citations across 5 tiers

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Competitive tyrosinase inhibition; reduces melanin synthesis

Researched effects

Skin brightening; melasma reduction; hyperpigmentation

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

Topical 0.01-0.1%

Known concerns

Minimal; slow visible results

Top-ranked picks

7 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma.

    Journal of drugs in dermatology : JDD · 2009 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 72.9

  2. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma.

    Journal of drugs in dermatology : JDD · 2013 — CLINICAL TRIALS · AUTHORITY 68.3

  3. Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12.

    Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2012 — CLINICAL TRIALS · AUTHORITY 68.2

  4. Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review.

    2025 — RESEARCH ARTICLES · AUTHORITY 34.5

  5. Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles.

    International journal of pharmaceutics · 2021 — RESEARCH ARTICLES · AUTHORITY 34.1

  6. Efficacy of Trifecting

    The Journal of clinical and aesthetic dermatology · 2018 — RESEARCH ARTICLES · AUTHORITY 33.8

  7. Combined topical delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color.

    Journal of drugs in dermatology : JDD · 2014 — RESEARCH ARTICLES · AUTHORITY 33.4

Full citation library

Year distribution

Randomised Controlled Trials

1
  1. 1.

    Hantash BM, Jimenez F · Journal of drugs in dermatology : JDD · 2009 · PMID 19663110

    Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl) was previously shown to competitively inhibit mushroom and human tyrosinase without the associated toxicity of hydroquinone. The aim of this split-face, randomized, double-blind and placebo-controlled pilot study was to determine the effect of twice-daily topical application of this oligopeptide (0.01% w/w) on moderate, recalcitrant melasma over a 16-week co…

Clinical Trials

2
  1. 2.

    Kassim AT, Hussain M, Goldberg DJ · Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2012 · PMID 22401652

    This prospective study evaluated the safety and efficacy of decapeptide-12 in conjunction with an antioxidant cleanser, glycolic-acid containing facial moisturizer and broad-spectrum sunscreen in the treatment of facial hyperpigmentation associated with chronic photodamage. Fifteen female subjects with Fitzpatrick skin types I through IV and documented photodamage were entered into the study, of whom 13 completed the study. Results were obtained at weeks 4, 8, 12, 18 and 24 and were assessed by…

  2. 3.

    Ramírez SP, Carvajal AC, Salazar JC, Arroyave G, et al. · Journal of drugs in dermatology : JDD · 2013 · PMID 23839199

    Melasma is a cutaneous disorder that primarily affects females of Hispanic and Asian descent. Previous studies have shown that use of a brightening system comprised of 0.01% decapeptide-12 cream, an antioxidant cleanser, a 20% buffered glycolic acid lotion, and a broad spectrum SPF 30 sunscreen yields good clearance of mild-to-moderate melasma in Caucasian and Asian volunteers. The present open-label, prospective, and multicenter study sought to determine the tolerability and efficacy of the abo…

Research Articles

4
  1. 4.

    Bhatia A, Hsu JTs, Hantash BM · Journal of drugs in dermatology : JDD · 2014 · PMID 24385124

  2. 5.

    Chen J, Bian J, Hantash BM, Albakr L, et al. · International journal of pharmaceutics · 2021 · PMID 34242628

    Hyperpigmentation is a common skin condition with serious psychosocial consequences. Decapeptide-12, a novel peptide, has been found to be safer than hydroquinone in reducing melanin content, with efficacy up to more than 50% upon 16 weeks of twice-daily treatment. However, the peptide suffers from limited transcutaneous penetration due to its hydrophilicity and high molecular weight. Therefore, decapeptide-12 was modified by adding a palmitate chain in an attempt to overcome this limitation. Mo…

  3. 6.

    Jiang L, Hino PD, Bhatia A, Stephens TJ, et al. · The Journal of clinical and aesthetic dermatology · 2018 · PMID 30666274

  4. 7.

    Pintea A, Manea A, Pintea C, Vlad RA, Bîrsan M, Antonoaea P, Rédai EM, Ciurba A. · 2025 · PMID 39858482

    One class of cosmetic compounds that have raised interest of many experts is peptides. The search for ingredients with good biocompatibility and bioactivity has led to the use of peptides in cosmetic products. Peptides are novel active ingredients that improve collagen synthesis, enhance skin cell proliferation, or decrease inflammation. Based on their mechanism of action, they can be classified into signal peptides, carrier peptides, neurotransmitter inhibitor peptides, and enzyme inhibitor pep…

Preprints (not yet peer-reviewed)

1
  1. 8.

    Chen J, Bian J, Hantash BM, Hibbs DE, Wu C, Kang L. · 2020

    Hyperpigmentation is a common skin condition with serious psychosocial consequences. Decapeptide-12, a novel peptide, has been found to be safer than hydroquinone in reducing content of melanin, with efficacy up to more than 50% upon 16 weeks of twice daily treatment. However, the peptide suffers from limited transcutaneous penetration due to its hydrophilicity and large molecular weight. Therefore, decapeptide-12 was modified by adding a palmitate chain in an attempt to overcome this limitation…

Case Reports

1
  1. 9.

    Hantash BM, Jimenez F · Journal of drugs in dermatology : JDD · 2012 · PMID 22527440

    Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl™) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma. The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physi…

Curated sources on file

3
  1. 1.
  2. 2.
  3. 3.
    Note: Primary literature for this commercial cosmetic peptide is limited; cited reviews summarize available preclinical and clinical evidence.

Continue reading